The enterprise with full technological cycle of genetically engineered insulin – from API to finished dosage forms. Full range of human recombinant insulin products manufactured based on proprietary technology. According to the charter, the main activity of the company is the production of pharmaceutical preparations and materials. Proximate strategic development envisages product portfolio enhancement with immunoprophylaxis products (vaccines) as well as innovative drugs and medical devices that meet all needs of people living with Diabetes, HIV/AIDS and Tuberculosis.
You must be logged in to keep track of the object.
Business activity: According to the charter, the main activity of the company is the production of pharmaceutical preparations and materials.
Average number of employees: 300
Land plot: no data
Legal obligations: no data
Additional information: Main markets: Ukraine, Moldova, Kazakhstan, CIS, Brazil and others.
Share proposed for privatization: 70,7016%
Starting price: ТВС
Investment advisor: not selected
| Part Capital | 70.7016 |
|---|---|
| Asset address | 02099 м. Київ, вул. Зрошувальна, 5 |
| Region | Kyiv city |
| Type of activity according to NACE | 21.20 - Виробництво фармацевтичних препаратів і матеріалів (основний); 46.46 - Оптова торгівля фармацевтичними товарами |
| Type of object of Large privatization | пакет акцій |
| Responsible for the preparation of the object | Фонд державного майна України |
| Contact person for the object | Залепа Надія Іванівна, +38 (044) 200-33-51, n.zalepa@spfu.gov.ua |
| The act by which the object is included in the List of privatization objects | Розпорядження Кабінету Міністрів України від 16 січня 2019 р. № 36-р "Про затвердження переліку об’єктів великої приватизації державної власності" (із змінами) |
| Order of the SPFU RV on the decision on privatization | від 08.06.2018 № 774 |
| Governing body | МОЗ |
| EDRPOU code | 00012925 |
You must be logged in to post a question.